natgillin/translations-raw huggingface dataset:
Imatinib Actavis is used when the patients are ‘Philadelphia-chromosome positive’ (Ph+).
Zdravilo Imatinib Actavis se uporablja pri bolnikih, pri katerih je bila ugotovljena prisotnost kromosoma Philadelphia (Ph+).
Imatinib Actavis may cause your body to retain water (severe fluid retention).
Zaradi zdravila Imatinib Actavis lahko telo zadržuje vodo (lahko pride do hudegaa zastajanja tekočine).
Imatinib Actavis will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours.
Zdravilo Imatinib Actavis vam lahko predpiše samo zdravnik, ki ima izkušnje z zdravili za zdravljenje krvnih rakov in solidnih tumorjev.
Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC(0-48h)).
Imatinib in N-demetilirani presnovek sta skupaj prispevala okrog 65 % radioaktivnosti v krvi (AUC(0- 48h)).
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23 % (90 % CI [1.16 - 1.30]).
Imatinib je v odmerku 400 mg dvakrat dnevno zaviral presnovo metoprolola s CYP2D6, tako da sta se Cmax in AUC metoprolola povečala za približno 23 % (90 % IZ [1,16 - 1,30]).
imatinib at 600 mg.
200 mg/m².
Imatinib in combination with chemotherapy induction (see Table 3) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients).
Imatinib je v kombinaciji z indukcijo s kemoterapijo (glejte preglednico 5) povzročil popolni hematološki odziv pri 93 % (147 od 158 za oceno primernih bolnikov) in pomembni citogenetični odziv pri 90 % (19 od 21 za oceno primernih bolnikov).
Imatinib in combination with chemotherapy induction (see Table 4) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients).
Imatinib je v kombinaciji z indukcijo s kemoterapijo (glejte preglednico 4) povzročil popolni hematološki odziv pri 93 % (147 od 158 za oceno primernih bolnikov) in pomembni citogenetični odziv pri 90 % (19 od
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib.
Imatinib povečuje povprečno Cmax in AUC simvastatina (substrat CYP3A4) 2-krat oziroma 3,5-krat, kar kaže na to, da imatinib zavira CYP3A4.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF - platelet- derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF – platelet- derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF - platelet- derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF-platelet- derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF - platelet- derived growth factor), PDGF-R in dejavnik matičnih celic (SCF - stem cell factor), c-Kit, in zavira celične dogodke, ki jih posredujeta PDGF in SCF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF-platelet- derived growth factor), PDGF-R in dejavnik matičnih celic (SCF-stem cell factor), c-Kit, in zavira celične dogodke, ki jih posredujeta PDGF in SCF.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF),PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF-platelet- derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
Imatinib may increase plasma concentration of other CYP3A4 metabolised medicinal products (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Imatinib lahko zveča plazemske koncentracije drugih zdravil, ki jih presnavlja CYP3A4 (na primer triazolo-benzodiazepinov, dihidropiridinskih blokatorjev kalcijevih kanalčkov, nekaterih zaviralcev reduktaze HMG-CoA, tj. statinov, itn.).
Imatinib medac 100 mg capsules are supplied in packs containing 60 capsules in blisters.
Imatinib medac 100 mg kapsule so na voljo v kartonskih škatlah, ki vsebujejo po 60 kapsul v pretisnem omotu.
Imatinib medac 100 mg hard capsules
Imatinib medac 100 mg trde kapsule
Imatinib medac 100 mg hard capsules are gelatin capsules of size “3” with orange body and cap.
Imatinib medac 100 mg trde kapsule so želatinske kapsule velikosti ”3” z oranžnim trupom in pokrovčkom.
Imatinib medac 100 mg hard capsules Imatinib
Imatinib medac 100 mg trde kapsule imatinib
Imatinib medac 100 mg hard capsules Imatinib medac 400 mg hard capsules Imatinib
Imatinib medac 100 mg trde kapsule Imatinib medac 400 mg trde kapsule imatinib
Imatinib medac 400 mg hard capsules
Imatinib medac 400 mg trde kapsule
Imatinib medac 400 mg hard capsules are gelatin capsules of size “00” with caramel body and cap.
Imatinib medac 400 mg trde kapsule so želatinske kapsule velikosti ”00” s trupom in pokrovčkom karamelne barve.
Imatinib medac 400 mg hard capsules Imatinib
Imatinib medac 400 mg trde kapsule imatinib
Imatinib medac contains lactose monohydrate
Zdravilo Imatinib medac vsebuje laktozo monohidrat
Imatinib medac is a ‘generic medicine’.
Imatinib medac je „generično zdravilo“.
Imatinib medac is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase. adult and paediatric patients with Ph+ CML in blast crisis. adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Zdravilo Imatinib medac je indicirano za zdravljenje pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev, pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi, odraslih in pediatričnih bolnikov s Ph+ KML v blastni krizi, odraslih in pediatričnih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo, odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji, odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor), odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim, odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP - dermatofibrosarcoma protuberans) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
Imatinib medac is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Uporaba zdravila Imatinib medac v nosečnosti ni priporočena, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
Imatinib medac is used to treat
Zdravilo Imatinib medac se uporablja
Imatinib medac is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Zdravilo Imatinib medac se uporablja pri bolnikih s kromosomom Philadelphia (Ph+).
Imatinib n=553
imatinib n = 553
Imatinib should not be used during pregnancy unless clearly necessary.
Imatinib ne smete uporabljati,pri nosečnicah, razen če je nujno potrebno.
Imatinib should not be used during pregnancy unless clearly necessary.
Imatiniba ne smete uporabljati,pri nosečnicah, razen če je nujno potrebno.
Imatinib Teva 100 mg film-coated tablets Imatinib Teva 400 mg film-coated tablets
Imatinib Teva 100 mg filmsko obložene tablete Imatinib Teva 400 mg filmsko obložene tablete
Imatinib Teva 100 mg hard capsules are non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap.
Zdravilo Imatinib Teva 100 mg trde kapsule so neprozorne oranžne kapsule s črno oznako 7629 na jedru in s črno oznako Teva na pokrovčku kapsule.
Imatinib Teva 100 mg hard capsules Imatinib Teva 400 mg hard capsules
Imatinib Teva 100 mg trde kapsule Imatinib Teva 400 mg trde kapsule
Imatinib Teva 400 mg hard capsules are non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
Zdravilo Imatinib Teva 400 mg trde kapsule so neprozorne oranžne kapsule s črno oznako 7630 na jedru in s črno oznako Teva na pokrovčku kapsule.
Imatinib Teva is a treatment for adults and children for:
Zdravilo Imatinib Teva je zdravilo za odrasle in otroke:
Imatinib Teva is also a treatment for adults for:
Zdravilo Imatinib Teva je tudi zdravilo za odrasle:
Imatinib Teva is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Uporaba zdravila Imatinib Teva v nosečnosti ni priporočena, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
Imatinib Teva is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Zdravilo Imatinib Teva se uporablja za zdravljenje odraslih s HES ali CEL, ki imajo posebno preureditev dveh genov, imenovanih FIP1L1 in PDGFRα; protuberantnega dermatofibrosarkoma (DFSP), vrste raka (sarkoma), pri kateri se celice pod kožo nenadzorovano delijo.
Imatinib Teva is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Zdravilo Imatinib Teva se uporablja za zdravljenje odraslih z MDS/MPD v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor);
Imatinib Teva is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Zdravilo Imatinib Teva se uporablja pri bolnikih s prisotnim kromosomom Philadelphia (Ph+).
Imatinib Teva may do the same to some other medicines.
Zdravilo Imatinib Teva lahko enako vpliva nekatera na druga zdravila.
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Imatinib je bil teratogen pri podganah, če so ga dobivale med organogenezo v odmerkih ≥ 100 mg/kg, kar je približno enako največjemu kliničnemu odmerku 800 mg/dan, izračunanemu na podlagi telesne površine.
imatinib – anticancer (used to treat cancer)
imatinib – zdravilo proti raku (uporablja se za zdravljenje raka)
imatinib, lapatinib (used to treat cancer)
imatinib, lapatinib (za zdravljenje raka)
imatinib, used to inhibit the growth of abnormal cells. angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
imatinib za zaviranje razmnoževanja nenormalnih celic zaviralci angiotenzinske konvertaze (na primer ramipril), ki jih uporabljamo za zdravljenje visokega krvnega tlaka ali drugih srčnožilnih obolenj.
imatinib, used to inhibit the growth of abnormal cells. angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
imatinib za zaviranje razmnoževanja nenormalnih celic. zaviralci angiotenzinske konvertaze (na primer ramipril), ki jih uporabljamo za zdravljenje visokega krvnega tlaka ali drugih srčnožilnih obolenj.
imatinib, used to treat a type of leukaemia. crizotinib, used to treat a type of lung cancer called non-small cell lung cancer.
imatinib, ki se uporablja za zdravljenje levkemije krizotinib, ki se uporablja za zdravljenje vrste raka pljuč, imenovanega nedrobnocelični rak pljuč
Imatinib-resistant or intolerant CML in accelerated phase at 400 mg twice daily
rezistenca na imatinib ali neprenašanje imatiniba v pospešeni fazi KML pri odmerku 400 mg dvakrat dnevno
Imatinib-resistant patients 44% (35–53) Major molecular response in patients achieving CCyRd (%) (95% CI)
Bolniki, odporni na imatinib 44% (35–53) Dober molekularni odziv pri bolnikih, ki so dosegli CCyRd (%) (95% IZ)
Imatinib-resistant patients 59% (50–68)
Bolniki, odporni na imatinib 59% (50–68)
Imatinib-resistant patients 72% (58–83)
Bolniki, odporni na imatinib 72% (58–83)
IMBRUVICA 140 mg hard capsules ibrutinib
IMBRUVICA 140 mg trde kapsule ibrutinib
IMBRUVICA 140 mg hard capsules ibrutinib
IMBRUVICA140 mg trde kapsule ibrutinib
IMBRUVICA 140 mg hard capsules.
IMBRUVICA 140 mg trde kapsule
IMBRUVICA are white opaque, hard capsules marked with “ibr 140 mg” in black ink on one side.
Zdravilo IMBRUVICA so bele, neprozorne trde kapsule s črno oznako "ibr 140 mg" na eni strani.
IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).
Zdravilo IMBRUVICA je kot samostojno zdravilo indicirano za zdravljenje odraslih bolnikov s predhodno nezdravljeno kronično limfocitno levkemijo (KLL) (glejte poglavje 5.1).
IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Zdravilo IMBRUVICA je kot samostojno zdravilo indicirano za zdravljenje odraslih bolnikov z Waldenstromovo makroglobulinemijo (WM - Waldenström’s macroglobulinaemia), ki so predhodno prejeli vsaj eno vrsto zdravljenja oziroma v prvi liniji pri bolnikih, ki niso primerni za kemoimunoterapijo.
Imbruvica can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in using cancer medicines.
Predpisovanje in izdaja zdravila Imbruvica je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Imbruvica contains the active substance ibrutinib.
Zdravilo Imbruvica vsebuje zdravilno učinkovino ibrutinib.
Imbruvica has been studied in 3 main studies in patients with chronic lymphocytic leukaemia.
Zdravilo Imbruvica so proučevali v treh glavnih študijah pri bolnikih s kronično limfocitno levkemijo.
IMBRUVICA is an anticancer medicine that contains the active substance ibrutinib.
IMBRUVICA je zdravilo proti raku, ki vsebuje zdravilno učinkovino ibrutinib.
Imbruvica is available as 140 mg capsules.
Zdravilo Imbruvica je na voljo v obliki 140-miligramskih kapsul.
IMBRUVICA should not be used during pregnancy.
Zdravila IMBRUVICA ne smete uporabljati pri nosečnicah.
IMBRUVICA should not be used during pregnancy.
Zdravila IMBRUVICA se ne sme jemati v času nosečnosti.
IMBRUVICA therapy should be withheld for any new onset or worsening grade ≥ 3 non-haematological toxicity, grade 3 or greater neutropenia with infection or fever, or grade 4 haematological toxicities.
Zdravljenje z zdravilom IMBRUVICA je treba prekiniti pri pojavu nehematološke toksičnosti stopnje 3 ali več ali pri poslabšanju že prej prisotnih znakov hematološke toksičnosti na stopnjo 3 ali več, pri nevtropeniji stopnje 3 s pridruženo okužbo ali zvišanjem telesne temperature ali pri znakih hematološke toksičnosti stopnje 4.
Imbruvica was also investigated in a main study involving 111 patients with mantle cell lymphoma that did not respond to or had come back after previous treatment.
Zdravilo Imbruvica so raziskali tudi v eni glavni študiji, v kateri je sodelovalo 111 bolnikov z limfomom plaščnih celic, ki se ni odzval na predhodno zdravljenje ali se je po njem ponovil.
Imbruvica was not compared with any other treatment in this study.
V tej študiji zdravila Imbruvica niso primerjali z drugimi zdravili.
Imepitoin also has a weak blocking
Poleg tega ima imepitoin šibek zaviralni učinek na kalcijeve
Imepitoin inhibits seizures via potentiation of the GABAA receptor-mediated inhibitory effects on the neurons.
Imepitoin okrepi zaviralni učinek na nevrone, ki ga posredujejo receptorji GABAA ter tako prepreči epileptične napade.
Imepitoin is a centrally acting antiepileptic substance which crosses the blood brain barrier without involvement of active transport or active clearance, resulting in immediate equilibrium between plasma and brain.
Imepitoin je osrednje delujoče zdravilo proti epilepsiji, ki prehaja skozi krvno-možgansko pregrado brez vpletenosti aktivnega transporta ali aktivnega očistka, kar povzroči takojšnje ravnovesje med plazmo in možgani.
Imepitoin is extensively metabolised prior to elimination.
Imepitoin se pred izločitvijo izčrpno presnovi.
Imepitoin partially activates the receptors for the neurotransmitter GABA in the brain.
Imepitoin delno aktivira receptorje za živčni prenašalec GABA v možganih.
imeprevir (a medicine used to treat hepatitis C infection);
imeprevir (zdravilo, ki se uporablja za zdravljenje okužbe s hepatitisom C),
imeprevir are expected.
povzročata aritmije.
Imidacloprid [mg/kg bw]
Imidakloprid [mg/kg t.m.]
Imidacloprid interferes with certain specific receptors (nicotinergic acetylcholine receptors) in the nervous systems of lice and fleas, which results in their subsequent paralysis and death.
Imidakloprid se veže na nekatere posebne receptorje (nikotinske acetilholinske receptorje) v živčevju uši in bolh, kar povzroči njihovo ohromitev in pogin.
Imidacloprid is effective against larval flea stages and adult fleas.
Imidakloprid deluje na ličinke in odrasle bolhe.
Imidacloprid is effective against larval flea stages and adult fleas.
Imidakloprid je učinkovit pri uničevanju odraslih bolh in njihovih ličink.
imiglucerase
(n = 39)
imiglucerase
dolgotrajnega
Imiglucerase, the active substance in Cerezyme, is a copy of this enzyme, which is produced by a method known as ‘recombinant DNA technology’: the enzyme is made by a cell that has received a gene (DNA), which enables it to produce the enzyme.
Zdravilna učinkovina v zdravilu Cerezyme, imigluceraza, je kopija tega encima, ki ga proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori ta encim.
Imiquimod is not recommended for the treatment of AK lesions with marked hyperkeratosis or hypertrophy as seen in cutaneous horns.
Uporaba imikvimoda ni priporočena za zdravljenje AK lezij z izrazito hiperkeratozo ali hipertrofijo, kot je na primer kožni rog.
Imiquimod should be used with caution in patients with reduced haematologic reserve (see section 4.8).
Imikvimod je treba uporabljati previdno pri bolnikih z zmanjšanimi hematološkimi vrednostmi (glejte poglavje 4.8).
Imlygic
Zdravilo Imlygic
Imlygic 106 PFU/mL injection talimogene laherparepvec Intralesional use
Imlygic 106 PFU/ml injekcija talimogen laherparepvek intralezijska uporaba
Imlygic 106 plaque forming units (PFU)/mL solution for injection
Imlygic 106 plakotvornih enot (PFU)/ml raztopina za injiciranje
Imlygic 106 plaque forming units (PFU)/mL solution for injection Imlygic 108 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic 106 plakotvornih enot (PFU)/ml raztopina za injiciranje Imlygic 108 plakotvornih enot (PFU)/ml raztopina za injiciranje talimogen laherparepvek
Imlygic 106 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic 106 plakotvornih enot (PFU)/ml raztopina za injiciranje talimogen laherparepvek
Imlygic 108 PFU/mL injection talimogene laherparepvec Intralesional use
Imlygic 108 PFU/ml injekcija talimogen laherparepvek intralezijska uporaba
Imlygic 108 plaque forming units (PFU)/mL solution for injection
Imlygic 108 plakotvornih enot (PFU)/ml raztopina za injiciranje
Imlygic 108 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic 108 plakotvornih enot (PFU)/ml raztopina za injiciranje talimogen laherparepvek
Imlygic contains approximately 30 mg (1.3 mmol) sodium in each 4 mL dose.
Zdravilo Imlygic vsebuje približno 30 mg (1,3 mmol) natrija v vsakem 4 ml odmerku.
Imlygic contains sorbitol (E420).
Zdravilo Imlygic vsebuje sorbitol (E420).
Imlygic is a type of advanced therapy medicine called a ‘gene therapy product’.
Zdravilo Imlygic spada v skupino zdravil za napredno zdravljenje, ki se imenujejo „zdravila za gensko zdravljenje“.
Imlygic may cause autoimmune reactions (an over-reaction of the body’s immune system).
Zdravilo Imlygic lahko povzroči avtoimunske reakcije (prekomeren odziv telesnega imunskega sistema).
Imlygic may cause infection at the injection site.
Zdravilo Imlygic lahko povzroči okužbo na mestu injiciranja.
Imlygic must not be refrozen once it has thawed.
Ko je zdravilo Imlygic odtajano, se ga ne sme ponovno zamrzniti.
Imlygic N = 295
Zdravilo Imlygic n = 295
Imlygic uses the melanoma cells’ own machinery to multiply, eventually overwhelming melanoma cells and killing them.
Zdravilo Imlygic za razmnoževanje uporablja mehanizem celic melanoma ter jih s tem sčasoma preobremeni in uniči.
Imlygic vs GM-CSF
Zdravilo Imlygic v primerjavi z GM-CSF
Immediate
ovojnina
Immediate
Stična
Immediate
Stična ovojnina
Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction
takojšnje in zapoznele preobčutljivostne reakcije npr. eksantem, urtikarija, pruritus, dermatitis, angioedem in anafilaktična reakcija
Immediate containers
Stična ovojnina
Immediate containers
Stični vsebniki
Immediate discontinuation of therapy, careful observation and initiation of appropriate supportive measures are recommended.
Priporočeni so prekinitev zdravljenja, skrbno spremljanje bolnika in izvajanje ustreznih podpornih ukrepov.